CHMP Recommends Gilead's Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast CancerBusiness Wire • 07/24/26
Can Gilead's Efforts to Develop New Treatments Solidify HIV Franchise?Zacks Investment Research • 07/23/26
Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026Business Wire • 07/21/26
Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and CureBusiness Wire • 07/21/26
Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral TherapyBusiness Wire • 07/21/26
Gilead Sciences (GILD) Sees a More Significant Dip Than Broader Market: Some Facts to KnowZacks Investment Research • 07/17/26
Is the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity?24/7 Wall Street • 07/15/26
Many Investors Are Still Treating Gilead Sciences Like a Has-Been HIV Stock. 4 Drug Launches This Year Could Prove Them Wrong.The Motley Fool • 07/12/26
Will the Label Expansion of Trodelvy Strengthen GILD's Oncology Portfolio?Zacks Investment Research • 07/06/26
Gilead Sciences (GILD) Dips More Than Broader Market: What You Should KnowZacks Investment Research • 06/25/26
Gilead's Breast Cancer Drug Trodelvy Wins FDA Nod for Expanded UseZacks Investment Research • 06/25/26
U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast CancerBusiness Wire • 06/24/26
For decades, the only first treatment for one of the deadliest breast cancers was standard chemotherapy. Now there are two newly approved drugs.WSJ • 06/24/26
Gilead Wins EC Approval to Expand Trodelvy's Label in Metastatic TNBCZacks Investment Research • 06/24/26
European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 InhibitorsBusiness Wire • 06/23/26
FDA Accepts Gilead's Filing for Weekly Oral Yeztugo for HIV PreventionZacks Investment Research • 06/16/26